Complement inhibition to treat myocardial infarction?

Area of Science:

• Cardiology
• Hematology
• Genetics

Background:

• Paroxysmal nocturnal haemoglobinuria (PNH) is a rare acquired disorder characterized by complement-mediated haemolysis and a prothrombotic state.
• Thrombotic complications are a significant cause of morbidity and mortality in PNH patients.

Observation:

• A middle-aged woman presented with acute myocardial infarction due to thrombotic occlusion of normal coronary arteries.
• The thrombosis was attributed to a hypercoagulable state secondary to a haemolytic crisis of PNH.
• The patient was managed conservatively with antithrombotic agents.

Findings:

• The clinical course was complicated by severe bleeding and recurrent thrombotic events.
• A massive intracerebral haemorrhage ultimately proved fatal.
• The rapid onset of complications precluded timely administration of eculizumab, a specific treatment for complement-mediated PNH.

Implications:

• This case highlights the critical importance of recognizing PNH as a cause of arterial thrombosis, even in the absence of typical PNH symptoms.
• Early diagnosis and initiation of complement inhibition therapy are crucial for preventing severe thrombotic and bleeding complications in PNH.
• Further research is needed to optimize the management of hypercoagulable states in PNH and improve patient outcomes.